DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2019年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3733

Title: Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.
Other Titles: フォン・ヴィレブランド因子のA1 ドメインに対する新規アプタマー (TAGX-0004) はARC1779よりも強く、Caplacizumabと同等に血栓形成を阻害する
Authors: Sakai, Kazuya
Someya, Tatsuhiko
Harada, Kaori
Yagi, Hideo
Matsui, Taei
Matsumoto, Masanori
Keywords: Arterial Thrombosis
Thrombotic Thrombocytopenic Purpura
aptamer
von Willebrand factor
Issue Date: 19-Dec-2019
Publisher: Ferrata Storti Foundation
Citation: Haematologica Early view (2019 Dec 19) doi: 10.3324/haematol.2019.235549
Abstract: von Willebrand factor (VWF) is a blood glycoprotein that plays an important role in platelet thrombus formation through interaction between its A1 domain and platelet glycoprotein Ib. ARC1779, an aptamer to the VWF A1 domain, was evaluated in a clinical trial for acquired thrombotic thrombocytopenic purpura (aTTP). Subsequently, caplacizumab, an anti-VWF A1 domain nanobody, was approved for aTTP in Europe and the United States. We recently developed a novel DNA aptamer, TAGX-0004, to the VWF A1 domain; it contains an artificial base and demonstrates high affinity for VWF. To compare the effects of these three agents on VWF A1, their ability to inhibit ristocetin- or botrocetin-induced platelet aggregation under static conditions was analyzed, and the inhibition of thrombus formation under high shear stress was investigated in a microchip flow chamber system. In both assays, TAGX-0004 showed stronger inhibition than ARC1779, and had comparable inhibitory effects to caplacizumab. The binding sites of TAGX-0004 and ARC1779 were analyzed with surface plasmon resonance performed using alanine scanning mutagenesis of the VWF A1 domain. An electrophoretic mobility shift assay showed that R1395 and R1399 in the A1 domain bound to both aptamers. R1287, K1362, and R1392 contributed to ARC1779 binding, and F1366 was essential for TAGX-0004 binding. Surface plasmon resonance analysis of the binding sites of caplacizumab identified five amino acids in the VWF A1 domain (K1362, R1392, R1395, R1399, and K1406). These results suggested that TAGX-0004 possessed better pharmacological properties than caplacizumab in vitro and might be similarly promising for aTTP treatment.
Description: 博士(医学)・甲第739号・令和2年3月16日
Copyright © 2019, Ferrata Storti Foundation.
This is a post-peer-review, pre-copyedit version of an article published in Haematologica. The final authenticated version is available online at: http://dx.doi.org/10.3324/haematol.2019.235549.
URI: http://hdl.handle.net/10564/3733
ISSN: 03906078
Academic Degrees and number: 24601A739
Degree-granting date: 2020-03-16
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2019年度

Files in This Item:

File Description SizeFormat
01甲739本文の要旨.pdf甲739本文の要旨1.57 MBAdobe PDFView/Open
02甲739審査要旨.pdf甲739審査要旨1.29 MBAdobe PDFView/Open
03甲739本文.pdf甲739本文7.76 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback